Q0245 – Injection, bamlanivimab and etesevimab, 2100 mg
HCPCS Level II code · Q codes: Temporary Codes
HCPCS codeQ0245
- Long description
- Injection, bamlanivimab and etesevimab, 2100 mg
- Short description
- Bamlanivimab and etesevima
- Pricing indicator
54Vaccinations- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
O1GImmunizations/Vaccinations- Added
- February 9, 2021
- Last change
- December 14, 2023 – No change
- Termination date
- December 13, 2023
Frequently asked questions
What is HCPCS code Q0245?
Q0245 is a HCPCS Level II code for injection, bamlanivimab and etesevimab, 2100 mg. It was discontinued on December 13, 2023.
Does Medicare cover Q0245?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby Q codes
- Q0234 – Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation only, 1 mg
- Q0235 – Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, not otherwise classified, 1 mg
- Q0237 – Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0238 – Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0239 – Injection, bamlanivimab-xxxx, 700 mg
- Q0240 – Injection, casirivimab and imdevimab, 600 mg
- Q0243 – Injection, casirivimab and imdevimab, 2400 mg
- Q0244 – Injection, casirivimab and imdevimab, 1200 mg
- Q0247 – Injection, sotrovimab, 500 mg
- Q0249 – Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg
- Q0477 – Power module patient cable for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0478 – Power adapter for use with electric or electric/pneumatic ventricular assist device, vehicle type
- Q0479 – Power module for use with electric or electric/pneumatic ventricular assist device, replacement only
- Q0480 – Driver for use with pneumatic ventricular assist device, replacement only
- Q0481 – Microprocessor control unit for use with electric ventricular assist device, replacement only
- Q0482 – Microprocessor control unit for use with electric/pneumatic combination ventricular assist device, replacement only
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.